Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity
0301 basic medicine
Mice, Inbred ICR
Norandrostanes
Antineoplastic Agents, Hormonal
Mice, Nude
Contraceptives, Oral, Synthetic
Article
Endometrial Neoplasms
3. Good health
Tamoxifen
03 medical and health sciences
Treatment Outcome
Non-alcoholic Fatty Liver Disease
Cell Line, Tumor
Animals
Heterografts
Humans
Female
Neoplasm Transplantation
DOI:
10.1038/srep43940
Publication Date:
2017-03-07T10:41:59Z
AUTHORS (14)
ABSTRACT
Abstract Tamoxifen is administered for estrogen receptor positive (ER + ) breast cancers, but it can induce uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD). Importantly, ten years of tamoxifen treatment has greater protective effect against ER than five such treatment. was also approved by the FDA as a chemopreventive agent those deemed at high risk development cancer. The side effects are substantial concern because these extended methods administration. In this study, we found that anordrin, marketed an antifertility medicine in China, inhibited tamoxifen-induced epithelial cell mitosis NAFLD mouse uterus anti-estrogenic estrogenic agent, respectively. Additionally, compared with tamoxifen, anordiol, active metabolite weakly bound to ligand binding domain ER-α. Anordrin did not regulate classic nuclear pathway; thus, affect anti-tumor activity nude mice. Taken together, data suggested anordrin could eliminate without affecting its activity.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (21)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....